A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Ovarian cancer is not silent killer — recognizing symptoms could help reduce misdiagnosison May 1, 2022 at 7:30 am
Thirty percent were given treatment for a different condition. And 13% were told there was nothing wrong. One major issue has been distinguishing ovarian cancer symptoms from those of common ...
- 'Having a happy gut with the right mix of bacteria could improve cancer treatments'on May 1, 2022 at 7:17 am
And here’s another one: it could improve cancer treatments. That is the conclusion of researchers from five clinical centres in the UK and across Europe studying our gut microbiome – the population ...
- Brain Cancer Canada funds Canada’s first genomics technology for rapid and precise brain tumour diagnosticson May 1, 2022 at 6:02 am
... Michael’s Hospital program to acquire and develop genome technology helping brain cancer patients. With this grant, genetic diagnostics, testing, and treatments will become more accessible to ...
- Study finds gut microbiota may change response to cancer treatmenton May 1, 2022 at 5:22 am
Washington [US], May 1 (ANI): According to Brigham and Women's Hospital, sequencing technology has recently shown that the gut microbiome may also play a role in cancer treatment along with its other ...
- Cancer treatment can't keep this Suns fan away from Footprint Center!on April 28, 2022 at 10:54 pm
PHOENIX — One season ticket holder hasn’t let cancer or trips for treatment keep her from watching the Phoenix Suns play at the Footprint Center! Instead, superfan Jessica Rosen feels like she is ...
- Vanessa Bayer Says the 'Special Treatment' from Her Childhood Cancer Battle Inspired New Serieson April 28, 2022 at 1:15 pm
"I would sort of use the fact that I was sick to get special treatment and I would sort of capitalize on the perks of having cancer." RELATED: SNL's Vanessa Bayer on Her Teenage Battle with Cancer ...
- ‘I’m a Cancer Exercise Specialist, and Here’s How To Work Out During the Treatment Process in a Way That Helps You Heal’on April 28, 2022 at 6:00 am
A cancer exercise specialist shares cancer exercise guidelines for safe workouts during chemotherapy, radiation and post-surgery.
- Can Complementary Therapies Ease Cancer Treatment Symptoms? What the Science Sayson April 27, 2022 at 9:25 am
People with cancer are increasingly likely to try integrative and complementary approaches to help their side effects ...
- Wireless device to provide new options for colorectal cancer treatmenton April 25, 2022 at 12:47 pm
For those diagnosed with colorectal cancer, surgery has been the only option that offers a solution. Unfortunately, surgery is frequently complicated by disease recurrence at the site of the original ...
via Bing News